The efficacy of angioplasty and stenting for patients with symptomatic intracranial atherosclerotic disease was recently evaluated in the stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis sammpris trial. Interestingly, the authors further analysed the outcome for those patients who met the sammpris criteria from the wasid trial. Primary balloon angioplasty for symptomatic, highgrade. In our opinion, a short segment symmetric petrous carotid artery stenosis has a very different procedural risk profile compared to a long segment asymmetric basilar artery stenosis. Finally, one of the most significant criticisms of the sammpris trial was that half of the patients in the trial were treated. Philip meyers has joined his colleagues in taking another look at the 2011 sammpris trial. Is the future of symptomatic intracranial atherosclerotic. All books on are public domain texts and free to download as pdf. Downloaded from at texas health resources on september 29, 2011. Compress pdf docs to reduce file size or convert them to word, excel, powerpoint or jpg without other dependencies. The sammpris trial results demonstrated that the majority of. The absorb iii findings come on the heels of the sammpris trial, which clearly demonstrated better outcomes with aggressive medical management for symptomatic intracranial stenosis compared with. The authors conducted a prospective phase i trial designed to assess the safety of submaximal angioplasty in patients with symptomatic icad. China angioplasty and stenting for symptomatic intracranial.
The randomised multicentre study stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis sammpris. This finding differs from the results of two recent trials comparing warfarin target inr, 2. Dec 19, 2007 frequency, risk factors, and outcome of coexistent small vessel disease and intracranial arterial stenosis. On the basis of the high 1month stroke andor death 14. Stenosis sammpris trial are listed in the supplementary appendix, available at. We will also address our criticism of the sammpris trial design in order to better design a future trial. The aggressive medical therapy based on the sammpris trial and a.
Relationship between vascular risk factors and location of. Aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris. Objective to determine baseline features that were associated with a high rate of a primary end point in the medical arm of the sammpris trial. Intensive medical therapy in the sammpris trial consisting of aspirin, 325 mgday, for entire followup. Intracranial stenosis is a common cause of ischaemic strokes, in particular, in the asian, african and hispanic populations. The sammpris trial suggested that aggressive treatment was superior to endovascular stenting in. Landmark neurology trials and papers steven gangloff, md.
Sammpris trial was lower than seen in the warfarinaspirin symptomatic intracranial disease wasid trial, this risk in either the ptas group or the medically managed group is still unacceptably high, 23%. Benefit of max medical management over stent for secondary stroke prevention in intracranial atherosclerosis. Middle cerebral artery stenosis is not frequent but a wellestablished cause of first and recurrent ischemic stroke. More articles will be added periodically, so please check back. The patients enrolled in the study had all previously survived. Response from the sammpris trial principal investigators regarding.
Primary angioplasty without stenting for symptomatic, high. Since the sammpris trial, stenting is no longer recommended as primary treatment. Aggressive medical treatment with or without stenting in. Randomized trial of patients in two predetermined strata based on the severity of carotid stenosis 30 to 69 percent and 70 to 99 percent who had had a hemispheric or retinal transient. The new standard for performance of intracranial angioplasty and. Have medical therapy and stenting been fairly compared. Middle cerebral artery stenosis in patients with acute. Astrazeneca supplied rosuvastatin, study devices supplied by stryker, 3 rd party monitoring of sites by stryker. However, the risk of recurrent stroke on intensive medical treatment of symptomatic intracranial stenosis is consistent with the two previous randomised controlled trials in younger cohorts, supporting the. Oral abstract presented at the 2012 international stroke. This presentation addressessome criticisms of the trial, emphasizes key knowledge gained from the study and proposes potential new directions for research in. The cadiss trial is, to our knowledge, the first randomized clinical trial in the treatment of carotid and vertebral dissection that recruited the target and had complete followup of all patients to 1 year. In this prespecified analysis, we aimed to investigate the relationship between risk factor control during followup and outcome of patients in the.
The safety and scientific validity of this study is the. Length of stenosis and location were not used as stratifying features. Response from the sammpris trial principal investigators. Here are just a few landmark neurology trials and articles every resident should know to keep up to date on important guidelines. The 30day rate of stroke or death in the ptas group 14. Importance the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial showed that aggressive medical therapy was more effective. It remains unclear whether angioplasty pta alone or in combination with other stent types ptas will yield similar results in perforatorbearing.
The wingspan stent system approved by the fda under a. Download slides article figuresmedia september 15, 2011 n engl j med 2011. Stenting for symptomatic intracranial arterial stenosis in. Aggressive medical treatment with or without stenting in high. Does the stenting versus aggressive medical therapy trial. In this trial vissit vitesse stent ischemic therapy, which was initiated soon after the start of sammpris, we examined percutaneous transluminal balloon angioplasty with stenting in symptomatic intracranial stenosis, but differed in its design, sample size, and type of intracranial stent used. Multicenter prospective trial of stent placement in. Patients with symptomatic stenosis of intradural arteries are at high risk for subsequent stroke.
The stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris study is the first stroke prevention trial to include protocoldriven intensive management of multiple risk factors. The study design for the sammpris trial has been published previously. Relationship between risk factor control and vascular events. In contrast, clinical experts tend to use welldesigned observational studies involving homogeneous populations and often scrutinize the. End of intracranial stenting for atherosclerosis or. Background and purpose a multicentre prospective registry study of individually tailored stenting for a patient with symptomatic intracranial atherosclerotic stenosis icas combined with poor collaterals. Angioplasty and stenting of intracranial arterial stenosis in. In the stenting and medical cohorts of the stenting and aggressive medical management for the prevention of recurrent ischemic stroke sammpris trial, we compared kaplanmeier km curves for the primary endpoint any stroke or death within 30 days of enrollment or ischemic stroke in the territory beyond 30 days using the logrank test and the percentages of patients achieving. Outcome of patients in the sammpris trial who had failed antithrombotic therapy at study enrollment. Finally, one of the most significant criticisms of the sammpris trial was that half of the patients in the trial. However, ptas has not been compared with medical management in a randomized trial.
Design of the vitesse intracranial stent study for. Cpd was the neurointerventional pi initially and then became the neurointerventional copi after df joined the study executive committee. The sammpris trial defined intracranial stenosis based on symptomatology and degree of stenosis. Design, setting, and participants a post hoc analysis of patients in the medical arm only of the sammpris trial. We have already had the sammpris trial, which was clearly negative for stent placement, and this trial was stopped at the time when sammpris was published and followup was done. Type and duration of exercise in the sammpris trial ncbi nih. We intend to highlight these past experiences and address future trials and trends in china. Outcome in patients previously on antithrombotic therapy in.
Factors associated with recurrent ischemic stroke in the medical. The study design for the sammpris trial has been published previ ously. Although the stenting versus aggressive medical therapy for intracranial arterial stenosis sammpris trial showed that medical therapy alone was superior to stenting plus medical therapy for preventing recurrent strokes in patients with symptomatic intracranial stenosis, we determined whether sammpris supported the use. The stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial was designed to assess whether percutaneous transluminal angioplasty and stenting ptas plus aggressive medical treatment is more effective than aggressive medical treatment alone in highrisk patients with this disease. Antiplatelet therapy vs anticoagulation therapy in. The results of the highly anticipated stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial revealed a 5. Antithrombotic therapy after acute coronary syndrome or.
From the zeenat qureshi stroke research center, department of neurology, university of minnesota, minneapolis, minnesota aiq, mfks. Effect of a balloonexpandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis. Sammpris randomized patients with 70 to 99% ic artery stenosis. Multicenter prospective trial of stent placement in patients. Design of the vitesse intracranial stent study for ischemic. The sammpris trial evaluated the use of the wingspan stent system in a similar highrisk patient population as the vissit study. The randomised multicentre study stenting and aggressive medical management for the prevention of recurrent stroke in intracranial stenosis sammpris showed 14.
The sammpris trial also revealed an interesting point. Clopidogrel plus aspirin for symptomatic intracranial atherosclerotic. Comparison of warfarin and aspirin for symptomatic. For more, you may enjoy the mobile app stroke trials, or this brief overview by the university of pittsburgh residency program. Enrollment in sammpris was stopped after 451 patients had been randomized primarily because the 30day rate of stroke and death was significantly higher in the stenting arm within 30 days of enrollment. Director of risk factor management and k23 grant sammpris industry support. In intracranial artery stenosis, adding angioplasty and. Astrazeneca supplied rosuvastatin, study devices supplied by stryker, 3 rd party monitoring. Outcome in patients previously on antithrombotic therapy. Pdf effect of a balloonexpandable intracranial stent vs. The recruitment of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis, an national institute of neurological disorders and stroke. The sammpris trial is also a great example of how cms the centers for medicare and medicaid services can accelerate our understanding of what best practice should be, he added. Pdf stenting versus aggressive medical therapy for intracranial.
However, it remained uncertain whether the low event rate could be of a long term. In the sammpris trial stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis, patients were enrolled with tia or stroke in the past 30 days and 70% to 99%. The periprocedural stroke rate in the sammpris trial because of perforator occlusion was 5. To remove the trial on a mac, use the acrobat uninstaller in the applicationsadobe.
Click on acrobat pro dc, and select uninstall from the menu. Similarly, the vissit the vitesse intracranial stent study for ischemic. Introduction the sammpris trial suggested that aggressive treatment was superior to endovascular stenting in patients with severe symptomatic intracranial atherosclerotic stenosis icas due to high complication rates in patients in the stenting group. Outline describe the epidemiology of intracranial stenosis. Volume 383, issue 9914, 2531 january 2014, pages 333341.
At the end of the study, with a median followup of 32 months, the rate of. Despite these early promising results, the sammpris trial reported a 30day rate of stroke or death of 14. Enrollment occurred between october 2008 and april 20 and included 227 patients. Submaximal angioplasty for symptomatic intracranial. Subgroup analysis of the sammpris trial showed a higher rate of periprocedural perforator strokes with the wingspan stent in the basilar artery in patients with. Results from the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial. Balloonexpandable stent vs medical therapy for intracranial. Intracranial stenting may be safer in clinical trials vs. Nov 28, 2016 beside the sammpris trial, three other low recruiting trials were cited, including a chinese study of 35 patients, which was translated from chinese into german language exclusively for this report. Details about the study design, patient enrollment, and followup. Recent trials the stenting vs aggressive medical therapy for intracranial arterial stenosis sammpris trial, the carotid occlusion surgery study coss and the vitesse intracranial stent study for ischemic. Entrance into the trial required the presence of a.
To uninstall your trial version on a windows device, close any open adobe software on your computer, open the windows control panel and doubleclick programs and features. The results of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris trial were published recently in the new england journal of medicine. The results of the stenting versus aggressive medical management for preventing recurrent stroke in intracranial stenosis sammpris study showed a 5. Results a total of 227 patients were included in the study, 82 of whom were. Angioplasty and stenting of intracranial arterial stenosis. Protocol for a prospective, multicentre registry study of. Sep 20, 2010 download the bible, the holy quran, the mahabharata, and thousands of free pdf ebooks on buddhism, meditation, etc. How recent data have impacted the treatment of internal. The prevalence of 5099% symptomatic intracranial stenosis increases steeply with age in predominantly caucasian patients with transient ischaemic attack and minor ischaemic stroke. Stenting versus aggressive medical therapy for intracranial. Stenting for symptomatic vertebral artery stenosis neurology. Mic is the principal investigator pi for the sammpris trial. Rigorous anaesthesia management protocol for patients with. Prevalence, predictors, and prognosis of symptomatic.
Sammpris trial was designed to assess whether percutaneous transluminal angioplasty and stenting ptas. Many factors contributed toward periprocedural stroke in. Sammpris is an ongoing randomized, multicenter clinical trial funded by the national institute of neurological disorders and stroke. The sammpris population was the right patient population to test. Early results of the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis trial showed that, by 30 days, 33 147% of 224 patients in the stenting group and 58% of 227 patients in the medical group had died or had a stroke percentages are product limit estimates, but provided insufficient data to establish whether stenting. As the principal investigators for the stenting and aggressive medical management for the prevention of recurrent ischemic stroke sammpris trial,1 we are compelled to address a few inaccuracies regarding this study in the recent editorial by dr alexander. Subgroup analysis of the sammpris trial showed a higher rate of periprocedural perforator strokes with the wingspan stent in the basilar artery in patients with symptomatic intracranial atherosclerotic stenosis icas. Sammpris, short for stenting and aggressive medical management for the prevention of recurrent ischemic stroke, was a large multicenter trial that compared two methods of stroke prevention. Mechanisms of stroke after intracranial angioplasty and. Intracranial angioplasty and stenting before and after. Frontiers the technique of endovascular intracranial.
Expert pdf editor x64 for windows xp,vista,7,8 64bit and later. Management of intracranial atherosclerosis after sammpris. The experience of treating icad in china, gained over the last two decades, is very rich and promising. The purpose of this study is to report the type and duration of physical activity in the sammpris trial. Background and purpose a multicentre prospective registry study of individually tailored stenting for a patient with symptomatic intracranial atherosclerotic stenosis icas combined with poor collaterals in china showed that the shortterm safety and efficacy of stenting was acceptable. Interventions the sammpris trial compared stenting with aggressive medical. Use the search function above to find our free pdf ebooks or use the category list to browse books. Relationship between risk factor control and vascular. In an accompanying editorial, dr joseph p broderick university of cincinnati college of medicine, oh, points out that sammpris is the third recent trial to show no benefit of revascularization.
1339 297 292 1067 700 259 1319 1197 978 949 841 192 1239 602 1078 723 1298 1067 925 1329 1198 1512 868 609 673 375 470 288 1446 917 696 804 1320 177